Bystolic 'significantly' reduces blood pressure in Hispanic patients

NEW YORK A Forest Labs drug used to treat mild to moderate hypertension “significantly” reduced blood pressure in Hispanic patients when used alone, according to post-marketing study data presented Monday at the American Society of Hypertension’s annual scientific meeting.

In a 277-patient phase 4 study, the drug Bystolic (nebivolol) reduced sitting systolic and disastolic blood pressure. The study included 113 Hispanic women and 164 men. According to Forest, Hispanics have higher rates of diabetes and obesity than Caucasians, and a study by the National Center for Health Statistics showed that more than 20% of adult Hispanics have hypertension.

“Bystolic is one of the only antihypertensives to have been prospectively evaluated for efficacy and safety in Hispanic patients, which is important given the lack of awareness, poor control and risk factors in this growing population,” University of Texas Southwestern Medical Center clinical assistant professor and study investigator Henry Punzi said. “These positive results show Bystolic is an effective treatment option with good tolerability for Hispanic patients with hypertension and add to the growing body of evidence in support of the clinical profile of the drug.”

Login or Register to post a comment.